The idea that heart disease mortality rises dramatically at menopause has been one of the truisms of medicine that spawned a generation of hormone use by women and led to the rise and subsequent fall of Prempro in the Women’s Health Initiative, the end-all-be-all study that failed to prove the truism. The truism is still so strongly believed that research to prove it right continues, using different hormone formulations and different cohorts of women, in the hopes that the hormonal fountain of youth was just misbranded and given to the wrong aged cohort.
Now comes a landmark study that suggests that what we’ve thought all along about heart disease and menopause may actually be wrong.
Dhananjay Vaidya and colleagues at Johns Hopkins and the University of Alabama have re-analyzed mortality data on men and women in the UK and US and concluded that, contrary to popular belief, heart disease rates and mortality do not increase dramatically with menopause, but rather rise more gradually as a function of age in both men and women.
“Our data show there is Read more »
*This blog post was originally published at The Blog That Ate Manhattan*
How could it have happened?
He was strong; do you remember how he could get uphill? He was fit; can you ever recall seeing him out of shape? His blood pressure was perfect, low even. He bragged about his exemplary cholesterol levels.
He was lean and mean.
Wait a minute…what was that about being mean?
When an endurance athlete in middle age is felled by a sudden heart attack, these questions always arise. It’s mysterious, as the idea holds that exercise and fitness should inoculate one from heart disease. But it does not.
There is more to the story of heart attacks than just the big five: genetics, smoking, high blood pressure, diabetes and cholesterol. Read more »
*This blog post was originally published at Dr John M*
Packing hearts on ice destined for transplantation may eventually become a thing of the past. The Organ Care System from TransMedics, which delivers a still-beating heart to a transplant patient, continues to show promise in clinical trials. UCLA recently reported that Rob Evans, a 61-year-old patient suffering from cardiomyopathy, is the most recent recipient of a heart delivered by the device.
We’ve actually covered the Organ Care System (OCS) several times before (we first caught wind of it in 2006). The device, however, is still classified as an investigational device by the FDA; it is undergoing phase II clinical trials in the United States at three sites: the Ronald Reagan UCLA Medical Center, the Cleveland Clinic, and New York-Presbyterian, Columbia University Medical Center.
Check out the UCLA press release explaining the technology and its use in the university’s Heart Transplant Program: Read more »
*This blog post was originally published at Medgadget*